Did you know that a single number can determine whether you need immediate prostate cancer treatment or can safely wait and monitor? Gleason scores provide the foundation for prostate cancer treatment decisions by evaluating how cancer cells appear under a microscope compared to normal prostate tissue. Scores range from low to high values. A Gleason score of 3+3=6 represents the lowest-risk cancer detectable by biopsy, in which cancer cells still look fairly similar to normal tissue. A 5+5=10 indicates cells that look very different from normal cells and grow in disorganised ways.
The first number represents the predominant pattern in your tissue sample (the appearance most often observed). The second describes the following most common pattern. This order matters for prognosis and treatment planning.
Your doctor can use your specific Gleason score to determine a suitable treatment approach. They may also consider other factors such as your age, overall health, and cancer stage.
Understanding the Gleason Grading System
The Gleason system assigns grades from 1 to 5 based on how the cells are arranged and structured. Contemporary pathology rarely uses grades 1 and 2 because they are similar to benign (non-cancerous) tissue. Grade 3 cells form individual, well-defined glands that closely resemble normal prostate tissue. Grade 4 cells show poorly formed, fused, or cribriform glands (cells arranged in a sieve-like pattern) with irregular borders. Grade 5 cells lack gland formation entirely. They appear as sheets, cords, or individual cells infiltrating tissue.
A pathologist, a healthcare professional who analyses tissue samples to diagnose disease, examines multiple biopsy cores (small tissue samples). They identify the two most prevalent patterns in each sample. The primary pattern (most common) becomes your first number. The secondary pattern (the second-most-common) becomes your second number. If only one pattern exists throughout the sample, the number doubles. Hence, a uniform Grade 3 pattern becomes a lower-risk score.
The distinction between patterns carries clinical weight. A Gleason score with three as primary differs meaningfully from one with four as primary despite identical sums. The configuration with Grade 4 as the predominant pattern may indicate more aggressive disease.
Grade Groups: The Modern Classification
In 2014, the International Society of Urological Pathology introduced Grade Groups to clarify risk stratification and improve patient communication. This system translates Gleason scores (a way of measuring how aggressive prostate cancer cells look under a microscope) into more intuitive categories:
Grade Group 1 encompasses Gleason 6 (3+3) cancers, representing the lowest risk category. These cancers grow slowly and rarely spread beyond the prostate. Many men with Grade Group 1 cancer may qualify for active surveillance rather than immediate treatment. Active surveillance involves regular monitoring without immediate treatment.
Grade Group 2 includes Gleason 3+4=7 cancers, where Grade 3 remains predominant. The presence of the Grade 4 pattern indicates a slightly higher risk. Treatment decisions are based on additional factors, including PSA levels (a protein produced by the prostate that can indicate cancer activity), clinical stage (how far the cancer has spread), and age.
Grade Group 3 contains Gleason 4+3=7 cancers, marking a transition to intermediate-high risk disease. The predominance of the Grade 4 pattern may warrant treatment consideration in most cases.
Grade Group 4 covers Gleason 8 cancers (4+4, 3+5, or 5+3). This indicates a high-risk disease, typically requiring multimodal treatment. Multimodal treatment combines different types of treatment, such as surgery or radiation, with hormone therapy.
Grade Group 5 includes Gleason 9-10 cancers (4+5, 5+4, or 5+5), representing the highest risk category. These cancers have the greatest likelihood of spread and recurrence.
What Your Specific Score Means
Gleason 6 (3+3)
This score indicates cancer cells that maintain a relatively typical glandular architecture. The cells still have a somewhat organised structure. The cancer typically grows slowly and remains confined to the prostate for many years. It rarely causes symptoms or spreads to other organs. Active surveillance protocols monitor these cancers through regular PSA tests, digital rectal exams, and repeat biopsies rather than immediate treatment.
Gleason 7 (3+4 vs 4+3)
The percentage of Grade 4 pattern impacts prognosis. Gleason 3+4=7, with a small proportion of Grade 4 patterns, behaves similarly to Gleason 6. Gleason 3+4=,7, with a larger proportion of Grade 4 pattern approaches the behaviour of 4+3=7. Your pathology report may include this percentage. Gleason 4+3=7 increases the risk of progression compared to 3+4=7. Your healthcare provider may recommend definitive treatment rather than surveillance based on your specific situation.
Gleason 8 (4+4, 3+5, 5+3)
These configurations indicate a disease requiring treatment. The absence of pattern 3 in Gleason 4+4=8 suggests uniform high-grade disease throughout the sampled tissue. Gleason 3+5=8 and 5+3=8, though less common, indicate the presence of the Grade 5 pattern. These warrant similar management.
Gleason 9-10
These scores indicate cancer with a risk of spread beyond the prostate. Gleason 9 (4+5 or 5+4) shows both high-grade patterns. The order suggests which predominates. Gleason 10 (5+5) represents a uniform Grade 5 pattern throughout the sampled tissue. This is a concerning configuration.
Factors That Influence Score Interpretation
Your Gleason score provides valuable information. However, treatment decisions incorporate multiple additional factors.
PSA density helps distinguish aggressive from slower-growing disease. Healthcare providers calculate this by dividing your PSA level by your prostate size.
Clinical stage may indicate whether cancer extends beyond the prostate capsule. Your doctor determines this through:
- Digital rectal exam (physical examination of the prostate)
- Imaging tests (such as CT or MRI scans)
The number of positive biopsy cores and the percentage of cancer in each core can provide insight into tumour volume. Positive biopsy cores are tissue samples that contain cancer.
MRI findings increasingly influence interpretation, particularly when results are discordant. Discordant results occur when different tests suggest conflicting findings. An MRI showing extensive disease despite low Gleason scores may prompt a repeat targeted biopsy. Minimal MRI abnormalities with borderline Gleason scores might support conservative management.
Patient factors also matter. Your healthcare provider can establish tailored treatment recommendations based on your individual circumstances. These include:
- Your age
- Overall health
- Preferences
- Life expectancy
An older patient with Gleason 3+4=7 cancer might choose active surveillance. Active surveillance involves careful monitoring without immediate treatment. A younger patient with identical pathology might opt for definitive treatment due to longer life expectancy.
Biopsy Limitations and Upgrading
Prostate biopsies sample a tiny portion of prostate tissue, creating potential for sampling error. Systematic biopsies, a method where samples are taken from multiple predetermined locations, might miss higher-grade areas. This is particularly true in large prostates or with anteriorly located tumours (tumours situated toward the front of the prostate). MRI-targeted biopsies (biopsies guided by magnetic resonance imaging to focus on suspicious areas) can improve accuracy but don’t eliminate sampling limitations entirely.
Upgrading occurs when surgical pathology (the examination of tissue removed during surgery) reveals higher Gleason scores than the initial biopsy. This can occur, most commonly with biopsy Gleason 6 upgrading to Gleason 7 at surgery. Factors that may indicate upgrading include:
- Higher PSA density (the amount of PSA relative to prostate size)
- Multiple positive cores (several biopsy samples containing cancer)
- High-volume disease on biopsy (cancer found in a large proportion of the sampled tissue)
Conversely, downgrading occurs less frequently. This typically involves a biopsy with Gleason 3+4=7 downgrading to Gleason 6 at surgery. This suggests the small Grade 4 component (the more aggressive cancer pattern) was removed entirely during biopsy.
💡 Did You Know?
The Gleason scoring system originated in the 1960s when Dr Donald Gleason examined prostate cancer specimens, identifying five distinct architectural patterns, different structures of cancer cells under the microscope, that correlated with patient outcomes, a classification system that remains fundamental to prostate cancer grading today.
Treatment Decisions by Score
Treatment recommendations align closely with Grade Groups, though individual factors modify standard approaches. Your doctor can develop a treatment plan tailored to your specific situation.
Grade Group 1 typically offers three options:
- Active surveillance (careful monitoring without immediate treatment)
- Focal therapy (targeted treatment of a specific area) for select cases with unifocal disease or cancer in just one location
- Definitive treatment for younger patients preferring immediate intervention
Grade Groups 2-3 generally warrant definitive treatment with radical prostatectomy (surgical removal of the prostate) or radiation therapy (using high-energy beams to destroy cancer cells). The choice depends on patient preference, age, comorbidities (other health conditions you may have), and cancer location within the prostate. Nerve-sparing surgery (a technique that attempts to preserve nerves controlling urinary and sexual function) remains feasible for many Grade Group 2 patients.
Grade Groups 4-5 require treatment, often combining modalities (different treatment approaches used together). Approaches include:
- Radical prostatectomy with extended lymph node dissection (removal of nearby lymph nodes to check for cancer spread), followed by adjuvant radiation (additional radiation after surgery) if adverse features exist
- Radiation therapy with extended hormone therapy (medications that reduce hormone levels that fuel prostate cancer growth)
- Systemic therapy (treatment that travels through the bloodstream to reach cancer cells throughout the body) may precede local therapy in select cases
Monitoring After Treatment
Post-treatment monitoring varies by initial Gleason score and treatment type. After radical prostatectomy, surgery to remove the prostate, PSA (prostate-specific antigen, a protein produced by the prostate) should become undetectable within several weeks. Any detectable PSA may indicate residual disease. Rising PSA confirms biochemical recurrence (the return of cancer detected by blood tests before symptoms appear).
Following radiation therapy, PSA gradually declines over an extended period. It reaches a nadir (the lowest point) that provides information about long-term outcomes. PSA rise above nadir defines biochemical recurrence after radiation.
Higher initial Gleason scores warrant closer monitoring and lower thresholds for salvage treatment (additional treatment after initial therapy has not fully worked). Healthcare professionals will determine specific monitoring schedules and treatment thresholds based on individual Gleason score, treatment response, and overall health profile. More aggressive cancers might receive adjuvant treatment (additional treatment given after the primary treatment) despite an undetectable post-surgery PSA. Less aggressive cancers may be observed even with detectable but stable PSA levels.
Preparation Steps for Your Pathology Discussion
- Review your complete pathology report, including all biopsy cores, not just the overall Gleason score. Note the number of positive cores, tumour percentage in each core, and any additional findings like perineural invasion (cancer cells near nerve fibres) or extraprostatic extension (cancer spreading beyond the prostate).
- Document your questions about specific score components. Focus on how your primary and secondary patterns may influence your health outcome. Ask about the Grade Group classification if it is not included in your report.
- Request visual aids during consultation. Many urologists can show microscopic images comparing your cancer patterns to normal tissue, making abstract scores more concrete.
- Consider a second opinion pathology review for borderline cases, particularly Gleason 6 vs seven or 3+4 vs 4+3 distinctions where treatment recommendations differ substantially. A pathology review involves having a second specialist examine your tissue samples to confirm the diagnosis.
- Discuss genomic testing eligibility (tests that analyse your cancer’s genetic makeup) if your score falls in the intermediate range. Molecular tests can provide additional information that may refine risk assessment beyond traditional parameters.
When to Seek Professional Help
- Your biopsy shows Gleason 7 or higher.
- PSA (a protein produced by the prostate that can indicate cancer activity) rises despite a negative initial biopsy.
- Questions persist about your Gleason score interpretation after reviewing pathology reports.
- Treatment recommendations seem inconsistent with your Gleason score and risk factors.
- You’re considering active surveillance (a monitoring approach where treatment is delayed while the cancer is carefully watched), but you are uncertain whether your Gleason score qualifies.
- Post-treatment PSA changes require interpretation in the context of your initial Gleason score.
- You would like a second opinion for borderline Gleason scores affecting treatment decisions.
Commonly Asked Questions
Can Gleason scores decrease over time?
Gleason scores reflect cellular architecture at the time of biopsy. They don’t spontaneously improve. However, some treatments, like hormone therapy, can alter cellular appearance temporarily. This doesn’t represent an actual grade reduction. The underlying genetic changes driving aggressive patterns persist despite treatment-induced morphologic changes.
Why don’t modern reports include Gleason scores below 6?
Contemporary pathology recognises that Gleason patterns 1 and 2 closely resemble benign tissue. They rarely appear in needle biopsies. Pattern 3 represents the lowest grade reliably diagnosed as cancer. Since biopsies require two patterns for scoring, 3+3=6 becomes the minimum reportable score. This eliminates confusion from scores suggesting a more benign disease than actually exists.
How accurate are Gleason scores from different pathologists?
Healthcare professionals who specialise in examining tissue from the urinary and reproductive systems demonstrate concordance for Gleason scoring. This is particularly true for Grade Groups at the extremes. Most significant variability occurs in distinguishing Gleason 3+4 from 4+3, where subtle morphologic differences carry substantial clinical implications. Cancer centres routinely perform internal review. A second opinion consultation may be recommended for borderline cases that affect treatment decisions.
Does tumour location affect Gleason score reliability?
Specific tumour locations prove harder to sample adequately with standard biopsy techniques. These include anterior tumours, transition zone cancers, and apical lesions. MRI-guided targeted biopsy can improve sampling accuracy for these locations. Post-biopsy inflammation can also obscure architectural patterns. This can affect score assignment if the biopsy is performed too soon after prior sampling.
Next Steps
Your Gleason score determines whether you need immediate treatment, can safely monitor your cancer, or require multimodal therapy. Focus on understanding your Grade Group classification and how additional clinical factors, such as PSA density and MRI findings, can modify your risk category. For intermediate-risk disease, genomic testing provides additional precision beyond traditional scoring.
If you’ve received a Gleason score of 7 or higher, are experiencing rising PSA levels, or have questions about treatment options based on your pathology results, consult with a qualified urologist for evaluation and personalised management planning.
